Key result
Updated 2023 ESC heart failure guidelines expand SGLT2i use to include HFmrEF and HFpEF.
Why the study?
Heart failure remains a severe priority problem in cardiology, and new modern drugs alongside expanded indications prompted an update to the 2023 European Society of Cardiology guidelines.
This article summarizes the updated 2023 ESC guidelines regarding new pharmacological treatments for acute and chronic heart failure.
AkutnĂ a chronickĂŠ srdeÄnĂ selhĂĄnĂ stĂĄle pĹedstavujĂ velmi zĂĄvaĹžnĂ˝ a prioritnĂ problĂŠm souÄasnĂŠ kardiologie. V souÄasnĂŠ dobÄ se v lĂŠÄbÄ srdeÄnĂho selhĂĄnĂ objevujĂ novĂŠ, modernĂ lĂŠky a zĂĄroveĹ se u tĂŠto diagnĂłzy rozĹĄiĹujĂ moĹžnosti jejich dalĹĄĂho pouĹžitĂ. Tyto poznatky byly shrnuty v aktualizaci guidelines pro srdeÄnĂ selhĂĄnĂ EvropskĂŠ kardiologickĂŠ spoleÄnosti v roce 2023. ÄlĂĄnek pĹinĂĄĹĄĂ struÄnĂŠ shrnutĂ novinek ve farmakoterapii dle tÄchto doporuÄenĂ.
No takes yet. Share an insight, caveat, or question.
Jaroslav Brotánek (2024) conducted a review in Acute and chronic heart failure. Pharmacotherapy according to 2023 ESC guidelines was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: